<DOC>
	<DOC>NCT02763215</DOC>
	<brief_summary>This is a 24-month study to assess copper (Cu) parameters in subjects with Wilson Disease treated with standard of care (SOC) medications. Data will be collected during routinely scheduled Wilson Disease clinic visits at approximately 6-month intervals. After providing informed consent, subjects meeting all inclusion and no exclusion criteria will be enrolled into the study as outpatients. Subject's routine Wilson Disease clinic visits will be scheduled according to the standard clinical practice at the study center and at the discretion of the treating physician at approximate 6-month intervals. At the time of enrollment, subjects will be receiving SOC therapeutic agents for the treatment of Wilson Disease. If treatment is interrupted or stopped during the course of the study, subjects will continue in the study and biological samples and clinical data will continue to be collected for the full 24-month study period. Dosing with SOC agents, which can include penicillamine, trientine, zinc, or a combination of a Cu chelator and zinc, will be individualized and managed by the treating physician at the study center according to standard clinical practice at the site.</brief_summary>
	<brief_title>The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Willing and able to give informed consent for participation in the study. Male or female subjects, aged 18 years or older as of signing the ICF. Receiving Standard of Care therapeutic agents (penicillamine, trientine, zinc, or copper chelators with zinc) for the treatment of Wilson Disease at the time of enrollment and for no more than 60 months prior to enrollment. Able to understand and willing to comply with study procedures and requirements, as judged by the Investigator. Established diagnosis of Wilson Disease. Adequate venous access to allow for collection of blood samples. Major systemic disease or other illness that would, in the opinion of the Investigator, compromise subject safety or interfere with the collection or interpretation of study results. In the opinion of the Investigator, the subject is likely to be noncompliant or uncooperative during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>